Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (August 2019)
22 slides from Clearpoint Neuro's investor presentation, Aug 28, 2019
Slide 1: ClearPoint: Precise Neuro Navigation & Therapy
CLEARPOINT PRECISE NEURO NAVIGATION & THERAPY : sioncan eal
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS ‘Statements herein concerning MRI Interventions, Ine. (the company") plans, growth and strategies may include orward-looking statements within the context ofthe federal secures laws. Statements regarding the Company's future ceverts, developments and future performance, as
Slide 3: Executive Summary
Executive Summary Unique platform technology ‘enabling prection MRlguided therapies to restore quality of fe for some ofthe most debilitating disorders Q oll Large, growing installed base in 55 0f250¢ leading neurology centers nUS. Procedure volume has grown ata 33% CAGR from 2013- 2018 € single-use
Slide 4: Neurological Disorders Treated Surgically Today
of Neurological Disorders Only a fraction of patients with debilitating neurological disorders are being treated surgically today Preve cOs Ge os oe Oe oe sOe Oe Cs ote ote os Gs <n Gs Gs ote cs Oe se te Oe a oe Oe <2 be cs ote cS eS Cs Gs ots On oe Oe Cs Gs oe Ca ots ee se oe Ge se ote ee os oe Oe
Slide 5: The Movement to Minimally Invasive Procedures Has Happened Everywhere Else in the Body
The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body This transition has always had two things in common: + More patients being treated + Procedures enabled by live image guidance
Slide 6: Traditional Stereotactic Neurosurgery is Limited
PRIMARY CHALLENGE Traditional Stereotactic Neurosurgery is Limited The Skull is Not ‘See Through’ + X-Ray and CT do not show structures of the brain + Large, Metallic Navigation Frames are not ‘compatible inside an MRI Magnet + Surgical Image Guidance in the Operating Room is not live but rather ‘Co
Slide 7: ClearPoint Neuro Navigation Platform
ClearPoint® Neuro Navigation a Platform ‘An MRI Compatible Navigation System Delivering Live MRI Guidance during the Procedure
Slide 8: Our Solution: Alignment and Insertion
Slide 9: MRIC & ClearPoint: A Proven Platform
‘UR COMPANY MRIC & ClearPoint: A Proven Platform Key Products: FDA C€ Marked Platforms; More than 3,000 Procedures Performed to Date eADQUARTERS EMPLOYEES Irvine,CA 40+ 19 sales | 19 production & development oisReveNve 20:9 REVENUE FORECAST $7.4m $10.0m - 1.0m" Razor / Razorblade ) model with 80% of
Slide 10: Broad and Growing User Base of Leading Neurosurgeons
[BROAD AND GROWING USER BASE OF LEADING NEUROSURGEONS
Slide 11: Platform Used to Place Laser Ablation Probes and Deliver Biologics and Drugs
PLAN NEURO Medtronic St. Jur Mepreat Pesto e ) NEURO! Our MRI-Guided therapy platform is currently being used t PLACE Laser DELIVER BioLocies ABLATION PROBES ‘AND DRUGS Medtronic Veyager VISUALASE reson MONTERIS PTC weerene Cveureants g@eyant BENE ) BlueRock uric PLATFORM RUNS. SIEMENS IMRis O
Slide 12: Our platform enables choice of precision-guided therapies and services
Our platform enables choice of precision-guided therapies and services CLEARPOINT ee A ttwore tiv tigre Rebels
Slide 13: Example: The Parkinson's Disease Patient
Example: The Parkinson’s Disease Patient Enabling Surgeons to choose the right tool for the right patient
Slide 14: Growth in Case Volume, Revenue
2013-2018 Growth in Case Volume, Revenue 2019 Revenue Forecast Renge of $10.0-$11.0 Mas of May, 2019 ©2010 ms mTERvENTIONS. ine |
Slide 15: Four Pillar Growth Strategy
Four Pillar Growth Strategy Target indications of > 150,000 procedures per year represents Potential Addressable Market for MRIC of $1B+
Slide 16: Grow Our Core Functional Neurosurgery Business
Grow Our Core Functional Neurosurgery Business: Focus on Complex Procedures Where Precision is Paramount ep Key Achievements Record Q2 quarterly case volume (197), ‘and Disposable Revenue © Increase to 10 sites using two-a-day procedure workflow, expanding ‘adoption driving volumes, efficiency + Ful
Slide 17: Become the Premier Partner for Biologics & Drug Delivery
‘Become the Premier Partner for Biologics & Drug Delivery: Focused Resources for Branding, Device Development and Distribution ep Key Achievements Raised $7.5 M via strategic investment led by PTC Therapeutics and first sales + Trained clinical specialists for Voyager \VY-AADC trial support; first t
Slide 18: Expand Into Direct Therapy Markets: Laser
THERAPY Expand Into Direct Therapy Markets: Achieve Greater Share of Total Procedure Revenue ee Key Achievements © Acquited License from CLS for Laser System and Applicators for Neurosurgery and Spine Indications * Opportunity to fine tune our NNavigations system to work seamlessly ‘with laser appli
Slide 19: Expand into Direct Therapy Markets: Neuro-Aspiration System
Expand into Direct Therapy Markets: Achieve frst-n-human case for our Neuro-Aspiration System ep Key Achievements Achieved FDA Clearance for the PURSUIT™ Neuro Aspiration System in December 2018, Collaboration with Mayo Clinic Affects 80,000 to 100,000 people inthe US each year, Three sites in the U
Slide 20: Achieve Global Scale and progress toward profit
Achieve Global Scale and progress toward profit Capabilities Established Sales Channel capable of distributing other surgical products + Current Revenue for non-neuro CLS Laser Applicators ‘Manufacturing Facility n Irvine capable of producing 5x current demand with existing footprint CE Mark labelin
Slide 21: Cash Flow From Operations (6 months)
~ 2015 - 2018 at Cash Flow From Operations (6 months) == == ep aD casi ar June 30,2019 $7.5 million
Slide 22: MRIC Capabilities: Executive Summary
MRIC CAPABILITIES | Executive Summary Ad neo nator cnt tenctonteote nermsto Seep morte See le Q, crecmcneaester Stismaleeneosy ae AO] rresesurevotame has grown 3% CAGR from 2013-2018
MRI Interventions — Investor Presentation (August 2019) on 6ix